The influence of tumor regression, solar elastosis, and patient age on pathologists\u27 interpretation of melanocytic skin lesions. by Titus, Linda et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
2-1-2017 
The influence of tumor regression, solar elastosis, and patient age 
on pathologists' interpretation of melanocytic skin lesions. 
Linda Titus 
Raymond L Barnhill 
Jason P Lott 
Michael W Piepkorn 
David E Elder 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Dermatology Commons, and the Oncology Commons 
Authors 
Linda Titus, Raymond L Barnhill, Jason P Lott, Michael W Piepkorn, David E Elder, Paul D Frederick, Heidi D 
Nelson, Patricia A Carney, Stevan R Knezevich, Martin A Weinstock, and Joann G Elmore 
The influence of tumor regression, solar elastosis, and patient 
age on pathologists’ interpretation of melanocytic skin lesions
Linda Titus, PhD, MA(1), Raymond L. Barnhill, MD(2), Jason P. Lott, MD, MHS, MSHP(3), 
Michael W. Piepkorn, MD(4), David E. Elder, MB Chb, FRCPA(5), Paul D. Frederick, MPH, 
MBA(6), Heidi D. Nelson, MD, MPH(7), Patricia A. Carney, PhD(8), Stevan R. Knezevich, MD, 
PhD(9), Martin A. Weinstock, MD, PhD(10), and Joann G. Elmore, MD, MPH(11)
(1)Departments of Epidemiology and of Pediatrics, Geisel School of Medicine at Dartmouth, and 
the Norris Cotton Cancer Center, Lebanon, NH
(2)Departments of Pathology, Institut Curie and Faculty of Medicine, University of Paris Descartes, 
Paris, France
(3)Cornell-Scott Hill Health Center, New Haven, CT
(4)Division of Dermatology, Department of Medicine, University of Washington School of Medicine, 
Seattle, WA; Dermatopathology Northwest, Bellevue, WA
(5)Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 
Philadelphia, PA
(6)Department of Medicine, University of Washington School of Medicine, Seattle, WA
(7)Providence Cancer Center, Providence Health and Services Oregon, and Departments of 
Medical Informatics and Clinical Epidemiology and Medicine, Oregon Health & Science 
University, Portland, OR
(8)Department of Family Medicine, Oregon Health & Science University, Portland, OR
(9)Pathology Associates, Clovis, CA
(10)Center for Dermatoepidemiology, VA Medical Center, Providence Department of Dermatology, 
Rhode Island Hospital; Departments of Dermatology and Epidemiology, Brown University, 
Providence, RI
(11)Department of Medicine, University of Washington School of Medicine, Seattle, WA
Abstract
It is not known whether patient age or tumor characteristics such as tumor regression or solar 
elastosis influence pathologists’ interpretation of melanocytic skin lesions. We undertook a study 
to determine the influence of these factors, and to explore pathologist characteristics associated 
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with the direction of diagnosis. To meet our objective, we designed a cross-sectional survey study 
of pathologists’ clinical practices and perceptions. Pathologists were recruited from diverse 
practices in ten states in the U.S. We enrolled 207 pathologist participants whose practice included 
the interpretation of melanocytic skin lesions.
Our findings indicated that the majority of pathologists (54.6%) were influenced toward a less 
severe diagnosis when patients were <30 years of age. Most pathologists were influenced toward a 
more severe diagnosis when patients were >70 years of age, or by the presence of tumor regression 
or solar elastosis (58.6%, 71.0%, 57.0%, respectively). Generally, pathologists with 
dermatopathology board certification and/or a high caseload of melanocytic skin lesions were 
more likely to be influenced, while those with more years’ experience interpreting MSL were less 
likely to be influenced. Our findings indicate that the interpretation of melanocytic skin lesions is 
influenced by patient age, tumor regression, and solar elastosis; such influence is associated with 
dermatopathology training and higher caseload, consistent with expertise and an appreciation of 
lesion complexity.
INTRODUCTION
Melanoma staging is determined by histologic characteristics that are known to influence 
patient outcomes including tumor depth, ulceration, and mitotic rate.(1–3) Of these, tumor 
depth was the first prognostic factor to be identified(4) and remains the strongest predictor 
of patient outcomes in the absence of tumor extension or metastases.(1)
While these characteristics form the basis of pathologists’ interpretations of melanocytic 
skin lesions, it remains unclear whether additional characteristics of the lesions or patients 
also influence interpretations. For example, younger patients, compared to older patients, 
have lower melanoma incidence rates(5) and higher melanoma survival rates.(6) 
Consequently, younger patient age might influence pathologists toward a less severe 
diagnosis, while older patient age may influence toward a more severe diagnosis.
The potential influence of partial tumor regression, uncommon in benign nevi but reported 
in up to 58% of melanomas,(7) is more difficult to anticipate. To the extent that tumor 
regression obscures depth of invasion, its presence might influence pathologists toward a 
more severe diagnosis. On the other hand, melanoma tumor regression may be thought to 
represent local host immune response,(8) a potentially favorable process. Studies of 
associations between partial tumor regression and metastasis or survival have produced 
mixed results, however, with some showing improved outcome(9, 10) and others showing 
worse outcome.(11–13)
Similarly, it is difficult to predict the potential influence of solar elastosis on the direction of 
pathologists’ diagnosis. More common in older patients,(14) solar elastosis is a microscopic 
marker of chronic sun exposure,(15) and a diagnostic criterion of certain melanoma 
subtypes.(16) Thus, its presence might increase suspicion of an atypical melanocytic lesion 
or melanoma, swaying pathologists toward a more severe diagnosis. On the other hand, 
several studies suggest improved melanoma outcome for patients affected by solar elastosis,
(3, 17, 18) which might influence pathologists toward a less severe diagnosis. Whether 
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pathologists consider these factors in their diagnostic interpretations is not known. To 
address this gap in knowledge, we sought to determine whether certain contexts (i.e., patient 
age, tumor regression, and solar elastosis) influence the severity of pathologists’ diagnoses 
when interpreting melanocytic skin lesions. We also assessed pathologist characteristics in 
relation to the direction of influence within each context found to be influential.
Although this report does not represent a traditional experimental study, it addresses the 
important issue of contexts that influence diagnoses that are central to the interpretation of 
much human experimental data.
METHODS
Study Design and Sample Selection
We conducted a study of pathologists who interpret melanocytic skin lesions (MSL), 
including benign nevi, dysplastic nevi, and melanoma. Institutional Review Board approval 
for all study procedures was obtained from the of the University of Washington, Fred 
Hutchinson Cancer Research Center, Oregon Health & Sciences University, Rhode Island 
Hospital, and Dartmouth College. Pathologists were recruited from community practices/
laboratories and academic medical centers in 10 states (CA, CT, HI, IA, KY, LA, NJ, NM, 
UT, and WA). We identified potential participants using Internet searches, professional 
organizations, and telephone calls to pathology laboratories/practices. Pathologists were 
invited to participate via email, postal mail, and telephone from July 2013 through August 
2014. Eligibility criteria included completion of residency training and/or fellowship 
training, interpretation of MSL within the previous year, expected continuation of 
interpreting MSL for the following two years while working in the same state, and verifiable 
address of practice location.
Survey Content
After consenting to participate, pathologists completed an online survey that elicited general 
demographic and professional information, including training, practice, and perceptions. A 
full copy of the survey is available at:http://depts.washington.edu/epidem/faculty/elmore-
joann.
Pathologists were asked whether each of certain contexts influenced the direction of their 
diagnosis of MSL. The potentially influential contexts included patient-level characteristics 
(patient age <30, patient age >70), tumor-level characteristics (areas of extensive tumor 
regression, significant solar elastosis).
Primary Outcome
The primary analytic outcome was the direction of diagnostic influence: influence toward a 
less severe diagnosis, no influence on diagnosis, and influence toward a more severe 
diagnosis. The vast majority of responses (≥96% within each context) included the no-
influence category and only one direction of influence; consequently, the primary outcome 
was dichotomized as follows: (a) “influence toward a less severe diagnosis” versus “no 
influence” or (b) “influence toward a more severe diagnosis” versus “no influence,” 
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depending on pathologists’ responses for each context. For example, in the context of tumor 
regression, 99% of pathologists reported either influence toward a more severe diagnosis or 
no influence on diagnosis. Thus, in this context, the primary outcome consisted of 
“influence toward a more severe diagnosis” versus “no influence.”
Pathologist Characteristics
We also explored pathologist characteristics in relation to diagnostic influence. Variables of 
interest included pathologist age, gender, residency training, dermatopathology fellowship 
training, dermatopathology board certification, MSL caseload (defined as the per month sum 
of benign MSL cases and melanoma/melanoma in situ cases), percentage of cases rendered 
as borderline or uncertain diagnoses in their final assessment, whether the pathologist 
requested second opinions from other pathologists (within our outside their practice) at least 
once per month, and whether pathologists requested specialized molecular tests, such as 
FISH or CGH.
Statistical Analysis
Preliminary analyses showed that pathologist age and years of interpreting MSL were highly 
correlated (r = 0.85; p < 0.0001), precluding simultaneous inclusion in multivariable models; 
thus, we chose to evaluate years of interpreting MSL due to its greater relevance. Due to 
almost perfect concordance between dermatopathology fellowship training and board 
certification, we chose dermatopathology board certification to represent specialized 
knowledge in dermatopathology. Dermatopathology board certification was highly 
correlated with higher MSL caseload (r = 0.64; p < 0.0001), and both were considered key 
variables. To incorporate both into our analysis, we created a three-level composite variable 
representing dermatopathology (DP) expertise: (1) no DP certification and low MSL 
caseload (<35 MSL/month), (2) no DP certification and high MSL caseload (≧35 MSL/
month), and (3) DP certification (regardless of caseload). Two variables, the frequency of 
using borderline/uncertain diagnosis in final assessments and the frequency of asking for 
second opinions, were dichotomized as yes/no because the relationship with the outcome 
was not linear.
Our primary analysis described the percent of pathologists reporting a direction of 
diagnostic influence within each of the four contexts. Correlation matrices were used to 
assess relationships between pathologist characteristics. The association between 
pathologists’ characteristics and the direction of diagnosis was displayed in frequency 
distributions and assessed in logistic regression models. We began by exploring bivariate 
(unadjusted) models to identify terms for inclusion in multivariable models. Variables 
associated with the outcome at p < 0.10 in bivariate models were assessed in multivariable 
models. Variables approaching statistical significance (p < 0.06) were retained in the final 
multivariable models to allow covariate adjustment. By convention, alpha was set at <0.05 
(two-sided tests) for statistical significance in the multivariable models. All statistical 
analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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Of the 864 potential pathologist participants initially identified, 301 met eligibility criteria 
and 207 (69%) completed the online survey. The majority (54%) were age ≥50 years (mean 
age 51 years) and male (59%) (Table 1). A minority (39%) were board certified in DP, with 
the remainder certified in anatomic pathology, clinical pathology, hematopathology, or 
cytopathology. The majority (69%) had interpreted MSL for less than 20 years, and for 63% 
the caseload was ≥ 35 MSL per month. Most pathologists (90%) reported ever using the 
terms borderline/uncertain in their final pathology report, and most (89%) reported they 
requested second opinions of other pathologists at least once per month.
Influence of Context on Direction of Diagnosis
The percent of pathologists reporting an influence of patient and tumor characteristics on the 
direction of their diagnosis within each context is shown in Figure 1. A majority of 
pathologists (54.6%) reported that young patient age (<30 years) would influence them 
toward a less severe diagnosis, and most (58.5%) reported that older patient age (>70 years) 
would influence them toward a more severe diagnosis. The majority of pathologists also 
reported they would be influenced toward a more severe diagnosis in the context of 
extensive tumor regression (71.0%) or by the presence of significant solar elastosis (57.0%). 
The full distribution of pathologist characteristics associated with direction of influence 
within each of the four contexts is provided in Appendix A.
Pathologist Characteristics and the Direction of Diagnosis, by Context
Patient Age <30 Years—Within the context of younger patients (age <30 years), only one 
variable, years of interpreting MSL, was associated with self-reported influence toward a 
less severe diagnosis in the bivariate analyses, so multivariable analysis was unnecessary. 
Compared to pathologists with less experience, those with ≥20 years of experience 
interpreting MSL were less likely (OR: 0.36; 95% CI: 0.20, 0.67; p=0.001) to be influenced 
toward a less severe diagnosis in the context of younger patient age (Table 2).
Patient Age >70 Years—Unadjusted analysis showed an association between the 
outcome and using the term borderline in a final diagnosis, but this variable lost significance 
when adjusted for other pathologist characteristics. Two variables, DP expertise, and years 
of interpreting MSL, remained associated with the outcome in adjusted analysis, and were 
included in the final multivariable model (Table 2). Compared to those without DP 
certification and with low MSL caseload, those with either a high MSL caseload (OR: 2.03; 
95% CI: 0.96, 4.29), or DP certification (OR: 2.82; 95% CI: 1.40, 5.69) were at least twice 
as likely to be influenced toward a more severe diagnosis when patients were older (global p 
= 0.012). Compared to pathologists with less experience, those with ≥20 years experience 
interpreting MSL were less likely to be influenced toward a more severe diagnosis (OR: 
0.33; 95% CI: 0.17, 0.63; p = <0.001).
Tumor Regression—Unadjusted analysis showed an association between the outcome 
and years of interpreting MSL, but this variable lost significance after adjustment for other 
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pathologist characteristics. Four variables remained associated with the outcome in adjusted 
models, and were retained in the final multivariable model (Table 2): dermatopathology 
expertise, years interpreting MSL, using the term borderline in a final diagnosis, and seeking 
second opinions. Compared to those without DP certification and with low MSL caseload, 
those with either high MSL caseload (OR: 2.87; 95% CI: 1.25, 6.60), or DP certification 
(OR: 2.91; 95% CI: 1.29, 6.53) (global p = .0.008) were more likely to be influenced toward 
a more severe diagnosis. Pathologists who ever used the terms borderline/uncertain when 
interpreting MSL were also more likely to be influenced toward a more severe diagnosis by 
tumor regression (OR: 4.73; 95% CI: 1.66, 13.53; p = 0.004), as were those who requested 
second opinions at least once per month (OR: 3.04; 95% CI: 1.12, 8.26; p = 0.029). 
Although the association was marginally significant, those with ≥20 years of experience 
interpreting MSL, compared to those with fewer years, were half as likely to be influenced 
toward a more severe diagnosis (OR: 0.49; 95% CI: 0.24, 1.02; p = 0.057).
Solar Elastosis—Two variables: years interpreting MSL, and ordering FISH/CGH or 
other molecular tests, were associated with the outcome in the unadjusted analysis, but were 
not statistically significant after adjustment for other pathologist characteristics. Three 
variables remained associated after adjustment, and were included in the final multivariable 
model: DP expertise, using borderline/uncertain diagnosis, and requesting second opinions 
(Table 2). Compared to non-DP certified, low-MSL volume pathologists, those with either 
high MSL volume (OR: 2.06; 95% CI: 0.98, 4.35), or DP certification (OR: 4.07; 95% CI: 
1.98, 8.38) were more likely to be influenced toward a more severe diagnosis (global p = 
<0.001). Pathologists who ever used the terms borderline/uncertain when interpreting MSL 
were also more likely to be influenced toward a more severe diagnosis (OR: 2.94; 95% CI: 
1.03, 8.37; p = 0.044), as were those who requested second opinions at least once per month 
(OR: 5.45; 95% CI: 1.92, 15.43; p = 0.001).
DISCUSSION
We identified four influential contexts that impact the severity of diagnosis: younger patient 
age, older patient age, tumor regression, and solar elastosis. Only one context, younger 
patient age, influenced pathologists toward a less severe diagnosis. The three remaining 
contexts influenced pathologists toward a more severe diagnosis.
Our results concerning patient age are compatible with studies showing a more favorable 
prognosis in younger patients than in older patients.(6) In addition, melanoma is less 
common in younger than in older individuals(5); thus, the prior probability of disease and 
the predictive value of a diagnosis of melanoma are greater in older populations.
A majority of pathologists in our study reported they were influenced toward a more severe 
diagnosis by melanoma with extensive tumor regression. Such influence may reflect 
longstanding concerns that tumors with regression have invaded beyond their measurable 
depth.(19) Consistent with this concern, some studies have shown a worse outcome for 
patients with regressed tumors (reviewed in Piepkorn & Barnhill, 2014).(20) Other studies, 
however, have indicated that tumor regression predicts better outcome, while still others 
have shown no association (reviewed in Piepkorn & Barnhill, 2014).(20) A recent meta-
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analysis of 14 studies,(10) published after our study was underway, noted a strong, inverse 
association between tumor regression and lymph node metastasis, implying more favorable 
survival, but heterogeneity was substantial among the analyzed studies.(10) It should also be 
noted that nearly half of melanomas disseminate without first invading the regional lymph 
nodes.(21, 22) Thus, the prognostic role of tumor regression, which has implications for 
diagnostic interpretation, and possibly for staging, remains unclear.
The majority of pathologists in our study were also swayed toward a more severe diagnosis 
by the presence of significant solar elastosis, a biological marker of chronic sun exposure.
(15) This finding seems inconsistent with the relatively slow radial growth rate of lentigo 
maligna melanoma, the histologic subtype for which solar elastosis is a diagnostic criterion,
(16) and with past studies showing a favorable influence of solar elastosis on prognosis.(3, 
17, 18) However, solar elastosis is an indicator of long term sun exposure, which is a known 
risk factor for lentigo maligna melanoma,(23) and is infrequently found with benign nevi, so 
its presence in a melanocytic skin lesion may increase suspicion of malignancy.
We also explored pathologist characteristics associated with influence on the direction of 
diagnosis. Pathologists with more years of MSL interpretation, who also were necessarily 
older, were less likely to be influenced toward a less severe diagnosis in the context of 
younger patient age. They were also less likely to be influenced toward a more severe 
diagnosis in the context of older patient age and tumor regression. While speculative, these 
findings may reflect complacency or over-confidence in those with long-term experience 
interpreting MSL.
Our findings were similar for pathologists who had high MSL caseloads, but lacked DP 
certification, and for those with DP board certification. Both groups were more likely to be 
influenced toward a more severe diagnosis in the contexts of older age, tumor regression, 
and solar elastosis. Those who designated tumors as borderline/uncertain in their final 
reports, and who requested a second opinion at least monthly were also more likely to be 
influenced toward a more severe diagnosis in contexts of tumor regression or solar elastosis. 
These pathologist characteristics are consistent with a higher level of sophistication and 
appreciation of lesion complexity, although requesting second opinions may also reflect 
laboratory policies.
Our study relies on self-reported data describing the influence of direction of diagnosis, but 
there is no reason to assume pathologists would incorrectly report their usual practice. We 
also did not compare the diagnostic accuracy of pathologists with more years of MSL 
interpretation to that of pathologists with specialized DP expertise. However, a recent 
analysis, based on the same group of pathologists, showed a significantly lower percentage 
of malpractice suits among those with DP fellowship training or board certification,(24) 
suggesting greater accuracy among those with specialized training. Our sample of 
pathologists, although arising from diverse settings and geographic areas, may not 
generalize to the population of US pathologists. However, we found no differences between 
pathologists who agreed to enroll in our study and those who did not. We also cannot be 
certain that the direction of influence reported by pathologists reflects their actual practice. 
Strengths of our study include the diversity of the study sample, which represents 
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pathologists in ten states, a 69% response rate among eligible participants, exceeding the 
national standard for physician surveys,(25) the detailed information gathered on the survey, 
and the quality of the analysis.
Our findings underscore complexity inherent in the subjective process of histological 
diagnosis of melanocytic skin lesions, revealing possible explanations for diagnostic 
discordance rates for melanoma and illustrating the potential for misclassification errors, 
with potentially substantial public health impacts, when identifying patient populations 
diagnosed with this maligancy. Future research may be helpful to assess the potential role of 
additional pathologist characteristics and other factors not evaluated here, as well as to 
determine whether the factors identified in this study may result in biases associated with the 
interpretation of more recent, “objective” diagnostic technology, including 
immunohistochemical markers, fluorescence in situ hybridization, comparative genomic 
hybridization, and gene expression profiling.
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Table 1
Characteristics of participating pathologists (n=207)
Pathologist characteristic number (%)
Age (yrs.)
 < 40 36 (17.4)
 40–49 59 (28.5)
 50–59 71 (34.3)
 ≥ 60 41 (19.8)
Mean age (SD) 51 (10.2)
Sex
 Male 123 (59.4)
 Female 84 (40.6)
Board certification
 Dermatopathology (DP) *** 81 (39.1)
 Other 126 (60.9)
Melanocytic skin lesion caseload per month**
 Low 76 (36.7)
 High 131 (63.3)
Composite variable: DP certified and melanocytic skin lesion caseload**
 Not DP certified, low caseload 72 (34.8)
 Not DP certified, high caseload 54 (26.1)
 DP certified 81 (39.1)
Years interpreting melanocytic skin lesions
 <20 143 (69.1)
 ≥20 64 (30.9)
Ever interpret melanocytic skin lesions as borderline or uncertain
 No 21 (10.1)
 Yes 186 (89.8)
Asks for second opinion at least once per month
 No 22 (10.6)
 Yes 185 (89.4)
Requests FISH/CGH or other molecular analysis
 No 128 (61.8)
 Yes 79 (38.2)
*
sum of number of melanomas + benign melanocytic skin lesions interpreted per month
**
average number of melanocytic skin lesions interpreted/month: low caseload <35/month; high caseload ≥35/month.
***
pathologists in this category have single or multiple certifications/fellowship training including dermatopathology
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